EGFR and lung carcinoma: As HER2 amplification was reported to be involved in acquired resistance to EGFR TKI, and meanwhile, ITK has been shown to be aberrantly activated in T-cell malignancies, further studies are warranted to evaluate the activity of ASK120067 against these kinases in lung cancer and in T-cell malignancies, respectively.